Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33043 OMN ...

Omnicell, Inc. (NASDAQ:OMCL) Q3 2021 Earnings Conference Call November 2, 2021 8:30 AM ET Company Participants Kathleen Nemeth - Vice President, Investor Relations Randall Lipps - Chief Executive Officer Roxanne Turner - Vice President, Corporate Responsibility Scott Seidelmann - Chief Commercial Officer Peter Kuipers - Chief Financial Officer Conference Call Participants Jessica Tassan - Piper Sandler Scott Schoenhaus - Stephens Inc. Iris Zhilin Long - Berenberg Capital Markets David Larsen - BTIG, LLC Ste ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33043 OMNICELL ...

Omnicell, Inc. (NASDAQ:OMCL) Q2 2021 Earnings Conference Call July 29, 2021 8:30 AM ET Company Participants Kathleen Nemeth - Investor Relations Randall Lipps - Chairman, President, Chief Executive Officer and Founder Scott Seidelmann - Executive Vice President and Chief Commercial Officer Peter Kuipers - Executive Vice President and Chief Financial Officer Conference Call Participants Jessica Tassan - Piper Sandler Scott Schoenhaus - Stephens Steve Halper - Cantor Matt Hewitt - Craig-Hallum Capital Group A ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33043 OMNICEL ...

Omnicell, Inc. (NASDAQ:OMCL) Q1 2021 Earnings Conference Call April 29, 2021 4:30 PM ET Company Participants Kathleen Nemeth - VP, IR Randall Lipps - Founder, Chairman, President and CEO Scott Seidelmann - EVP and Chief Commercial Officer Peter Kuipers - CFO Conference Call Participants Iris Long - Bearing Bird Capital Management Scott Sean - Stephens Matt Hewitt - Craig-Hallum Capital Bill Sutherland - The Benchmark Company Operator Good day, and thank you for standing by. Welcome to the Omnicell's First Q ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33043 OMNICELL, INC. (Exact name of regis ...

Kathleen Nemeth Good afternoon and welcome to the Omnicell fourth quarter and full year 2020 financial results call. On the call with me today are Randall Lipps, Omnicell Founder, Chairman, President and CEO, Scott Seidelmann, Executive Vice President and Chief Commercial Officer, and Peter Kuipers, Executive Vice President and Chief Financial Officer. This call will include forward-looking statements subject to risks, uncertainties and other factors that could cause actual results to differ materially from ...

Financial Data and Key Metrics Changes - In Q4 2020, revenues were $249 million, an increase of $36 million from the prior quarter and up 0.4% year-over-year [41] - Full year 2020 revenues totaled $892 million, a decrease of $5 million from 2019 [41] - Q4 GAAP earnings per share were $0.37, down from $0.51 in Q4 2019, while full year GAAP EPS was $0.74, down from $1.42 in 2019 [41][42] - Non-GAAP EBITDA for full year 2020 was $159 million, a 4% decrease from $167 million in 2019 [43] - Q4 non-GAAP EBITDA was $52 million, an increase of 13% compared to $46 million in Q4 2019 [43] - Total product bookings for 2020 were $1 billion, a 23% increase from $830 million in 2019 [44] - Product backlog at the end of 2020 was $924 million, a 57% increase year-over-year [44] Business Line Data and Key Metrics Changes - The company achieved record product bookings exceeding pre-pandemic guidance, with substantial increases in new customer wins [11][12] - SaaS, subscription software, and tech-enabled services bookings significantly exceeded plans for the year, with a forecasted 50% CAGR from 2020 to 2025 [15][51] - Advanced services are expected to reach 20% to 30% of total revenues by 2025, driven by the urgency for digitization in healthcare [51] Market Data and Key Metrics Changes - Over half of the top 300 health systems in the U.S. are now Omnicell customers, with long-term sole source contracts with 145 of them [12] - Internationally, the company is gaining momentum in Asia, with recent customer wins in Singapore and Japan [33] Company Strategy and Development Direction - The company is focused on the autonomous pharmacy model, which combines hardware, software, and services to improve healthcare delivery [26] - A long-term financial roadmap targets a 14% to 15% compounded annual revenue growth rate from 2021 to 2025 [22] - The company aims to expand its non-GAAP EBITDA margin from 21% in 2021 to 25% by 2025 [22][56] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position to drive growth and deliver value for shareholders, emphasizing the strategic relevance of their solutions in the current healthcare environment [20][62] - The pandemic has highlighted the need for increased automation and digitization in pharmacy management, which aligns with the company's offerings [16] Other Important Information - The company published initial ESG disclosures in December, focusing on sustainability and diversity initiatives [19] - Cash balance as of December 31, 2020, was $486 million, with cash flow from operations increasing significantly year-over-year [47] Q&A Session Summary Question: Details on long-term sole source agreements with health systems - Management indicated that these agreements are typically 10 to 15 years and are primarily driven by advanced services [66][67] Question: Growth expectations for SaaS subscription revenue - The 50% CAGR for SaaS and tech-enabled services is organic, with no acquisitions factored in [69] Question: Progress on EnlivenHealth and 340B Link platforms - The CareScheduler module has rapidly increased its pharmacy store sign-ups, with expectations for continued growth as retail pharmacies play a larger role in vaccine distribution [78] Question: Lifecycle of a sole source customer - The installation process varies, but typically includes multiple implementations over several years, allowing for a recurring revenue stream [95][97]

Investor Presentation October 2020 Safe Harbor Statement | --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------| | | | | To the extent any statements contained in this presentation deal with information that is not historical, the ...